✦ New
Top 80 item(s) from the CED news pipeline as of March 08, 2026.
- 97Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
- 97Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
- 97From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
- 97Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
- 96New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
- 96New Top Cannabis Regulator Sets Priorities In First Board Meeting
- 95Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
- 952 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
- 95New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
- 95Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
- 95Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature
- 95Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
- 95Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
- 95Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
- 95Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
- 95As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
- 95The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
- 95Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
- 95New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
- 95Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
- 95Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
- 92Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
- 92Ohio THC drink ban draws lawsuit from Cincinnati breweries
- 92Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
- 92Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
- 92Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
- 902026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
- 90Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
- 88Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
- 85Study reveals cannabis compounds reduce threat of fatty liver disease | Health
- 85Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
- 85TPS Cannabis News – StratCann
- 85InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
- 85Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots
- 85Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
- 85West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
- 85Study highlights positive, negatives of medical marijuana – WKRN News 2
- 85The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
- 85Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
- 85‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
- 85One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword
- 85Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN
- 85Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook
- 85Perceptions of the relative harmfulness of marijuana and alcohol among adults in Oregon.
- 84What’s Really Happening With Cannabis ETF MSOS? – The Dales Report
- 82Study reveals cannabis compounds reduce threat of fatty liver disease – Daily Journal
- 82Scientists are raising new concerns about marijuana use in teens – KPBS
Research continues to build a concerning picture around adolescent cannabis use and its association with elevated risk for psychiatric conditions, including psychosis, depression, and anxiety disorders. The developing brain, particularly during the teenage years, appears to be especially vulnerable to the neurochemical disruptions that cannabinoids can produce, with THC’s interaction with the endocannabinoid system potentially altering normal neurodevelopmental trajectories. Clinicians and public health researchers are increasingly calling for clearer communication about these risks, particularly as cannabis potency has risen substantially and cultural perception of harm has declined among younger populations. - 82Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
Sublingual cannabis extract administration has demonstrated meaningful reductions in myofascial pain among patients with temporomandibular disorders, a condition historically resistant to conventional pharmacological approaches. The findings add to a growing body of evidence supporting cannabinoid-based interventions for chronic orofacial pain, where inflammation and central sensitization play significant roles. Sublingual delivery offers practical advantages in this population, including rapid mucosal absorption and the ability to titrate dosing with reasonable precision.
Why it matters: Patients with chronic jaw and facial pain who have not found relief through standard treatments now have emerging clinical trial evidence supporting sublingual cannabis extracts as a potential therapeutic option worth discussing with their provider. - 81Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure
Emerging research is exploring whether placental biomarkers can serve as early indicators of schizophrenia risk, particularly in the context of prenatal cannabis exposure. THC crosses the placenta and can disrupt fetal neurodevelopment by interacting with the endocannabinoid system during critical windows of brain formation. This line of inquiry raises important questions about how prenatal THC exposure may prime neurobiological pathways associated with psychosis susceptibility later in life. - 81Scientists are raising new concerns about marijuana use in teens – YouTube
Adolescent cannabis use remains one of the most clinically significant concerns in cannabis medicine, as the developing brain is uniquely vulnerable to the effects of THC through at least the mid-twenties. Research consistently points to associations between early, frequent cannabis use and disruptions in neurodevelopmental trajectories, including effects on memory, attention, and emotional regulation. The concentration of THC in today’s products is substantially higher than in previous decades, which raises the stakes for any conversation about youth exposure and risk. - 78A huge study finds a link between cannabis use in teens and psychosis later – NPR
A large study has found an association between cannabis use during adolescence and increased risk of developing psychosis later in life. These findings underscore the importance of protecting the developing brain, as adolescents appear to be more vulnerable to cannabis-related neuropsychiatric outcomes than adults.
Why it matters: This large-scale study reinforces existing evidence that adolescent cannabis exposure is associated with increased psychosis risk, likely reflecting cannabis-related disruption of dopaminergic and endocannabinoid signaling during neurodevelopmental critical periods. Clinicians should screen teenage patients for cannabis use as part of routine mental health assessment, particularly those with personal or family history of psychotic disorders. These findings also support age-restricted access policies as a harm-reduction priority within cannabis regulatory frameworks. - 78Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape
Emerging research continues to reinforce what clinicians have observed for years: adolescent cannabis use, particularly during critical neurodevelopmental windows, is associated with a meaningful increase in risk for serious psychiatric conditions including psychotic and bipolar disorders. The developing brain remains uniquely vulnerable to exogenous cannabinoids, and the endocannabinoid system plays a central role in synaptic pruning and neural circuit maturation during the teenage years. This does not mean cannabis causes these conditions in every user, but it does underscore the importance of age-appropriate clinical guardrails and honest conversations about risk.
Why it matters: 🧠 New research highlights what cannabis clinicians have been saying for years: the teenage brain handles cannabis very differently than the adult brain. Here’s what you need to know: 🔬 Teen cannabis use is linked to increased risk of psychotic and bipolar disorders 📊 The developing brain’s endocannabinoid system is uniquely vulnerable ⏳ Delaying use until the mid-20s is a key harm reduction strategy 🗣️ This is about smart policy and honest conversations, not prohibition 👨⚕️ Adult medical cannabis use is a separate clinical conversation entirely 💡 Being pro-cannabis AND pro-safety means taking age of initiation seriously. #CannabisMedicine #MentalHealthAwareness #HarmReduction #AdolescentHealth #BrainDevelopment #CannabisEducation #CEDClinic #DrBenCaplan #CannabisResearch - 78Brain Researchers Finally Know Why Cannabis Use Increases Appetite – The Debrief
The appetite-stimulating effects of cannabis, commonly known as “the munchies,” have long been observed clinically but the precise neurological mechanisms were not well characterized until recently. Research has now identified how cannabinoids interact with specific brain circuits to drive increased appetite, independent of the type or palatability of food available. This distinction is clinically meaningful because it suggests the effect is centrally driven rather than a response to sensory reward or food preference. - 78Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds
Research examining adolescent cannabis use has consistently identified a meaningful association between early initiation and elevated risk for psychotic spectrum disorders in adulthood, with the biological vulnerability of the developing adolescent brain playing a central role in this relationship. The endocannabinoid system undergoes significant maturation throughout adolescence, and exogenous cannabinoids introduced during this window appear to disrupt neurodevelopmental trajectories in ways that can have lasting psychiatric consequences. Potency of the cannabis product matters considerably here, as contemporary high-THC formulations represent a substantially different exposure profile than products studied in earlier decades. - 78The association between cannabis use and brain reward anticipation: a 12-month … – Nature
Research examining cannabis use and brain reward circuitry has produced inconsistent results, with some studies suggesting blunted responses to non-drug rewards and others showing minimal or no effect. The complexity likely stems from variables including frequency of use, age of initiation, cannabinoid content, and individual neurobiological differences that are difficult to control across study populations. Longitudinal designs tracking participants over time offer a more rigorous framework for understanding whether reward processing changes precede cannabis use, follow from it, or reflect a bidirectional relationship. - 78THC levels in blood and urine are "unreliable" indicators of driving impairment – leafie
The relationship between THC concentration in biological fluids and actual driving impairment is far more complex than a simple number can capture. THC is highly lipophilic, meaning it distributes rapidly into tissues and does not remain in blood proportionally to psychoactive effect, which makes blood levels a poor proxy for functional intoxication. Unlike alcohol, where blood concentration correlates reasonably well with impairment, cannabis pharmacokinetics vary dramatically based on frequency of use, individual metabolism, tolerance, and the presence of other cannabinoids. - 78Study Links Prenatal Cannabis Exposure To Schizophrenia – New Telegraph
Emerging research suggests that prenatal cannabis exposure may leave measurable biological signatures in placental tissue that are associated with increased schizophrenia risk in offspring. The placenta acts as a dynamic interface between maternal and fetal environments, and cannabinoids can cross this barrier and influence fetal neurodevelopment during critical windows of brain formation. These findings add biological plausibility to epidemiological signals that have long suggested a connection between gestational cannabis use and downstream psychiatric vulnerability in children. - 78The Endocannabinoid System’s Contribution to Placebo Analgesia – bioRxiv
The endocannabinoid system appears to play a meaningful role in mediating placebo analgesia, suggesting that the brain’s expectation of pain relief may partially operate through the same cannabinoid signaling pathways activated by cannabis-based medicines. This finding adds biological plausibility to the long-debated question of how much overlap exists between expectation-driven pain relief and pharmacologically induced analgesia. Understanding this mechanism has implications for how clinical trials are designed, how placebo responses are interpreted in cannabis pain studies, and how clinicians counsel patients about the neuroscience behind their treatment responses. - 78Modulating the endocannabinoid system in alcohol use disorder: A translational systematic …
The endocannabinoid system plays a central role in regulating reward circuitry, stress response, and impulse control, all of which are disrupted in alcohol use disorder. Cannabinoid receptors, particularly CB1 and CB2, along with endogenous ligands like anandamide and 2-AG, modulate dopaminergic and GABAergic pathways that drive craving, withdrawal, and relapse behavior. Research into ECS-targeted therapies, including FAAH inhibitors and neutral CB1 antagonists, represents a meaningful shift toward biologically informed treatment of addiction rather than purely behavioral approaches. - 78Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – The Hill
Cannabis hyperemesis syndrome (CHS) is a paradoxical condition in which chronic, heavy cannabis users develop cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is frequently misdiagnosed for months or years because patients and clinicians alike associate cannabis with antiemetic properties, creating a counterintuitive diagnostic barrier. As high-potency THC products have become more widely available and socially normalized, the frequency of CHS presentations in emergency departments has increased, making clinician and patient awareness more urgent than ever.
Why it matters: If you use cannabis daily and experience recurring vomiting that improves with hot showers, you may have cannabis hyperemesis syndrome, and stopping cannabis use is currently the only reliable cure. - 78Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online
Research comparing cannabis use disorder to other substance use disorders is an important area of inquiry because it helps clinicians understand the relative psychiatric burden associated with problematic cannabis use in the context of a rapidly changing legal and cultural landscape. Propensity-score-matched study designs are valuable here because they attempt to control for the many confounding variables that make substance use populations inherently difficult to compare fairly. Understanding how cannabis use disorder stacks up against alcohol, opioid, or stimulant use disorders in terms of psychiatric outcomes can meaningfully inform screening, treatment prioritization, and public health messaging.
Why it matters: Patients who use cannabis heavily should know that research is actively examining how cannabis use disorder compares to other substance use disorders in terms of real-world psychiatric risks, which may affect how clinicians screen and counsel them going forward. - 78Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …
Emerging research from major academic institutions is challenging longstanding assumptions that cannabis use accelerates cognitive aging or increases dementia risk in older populations. The data suggest that lifetime exposure to cannabis, when examined in older adult cohorts, does not appear to correlate with measurable declines in cognitive function or elevated dementia incidence. This adds important nuance to how clinicians should counsel aging patients who use or are considering cannabis for symptom management.
Why it matters: Older adults who have used cannabis throughout their lives, or who are considering it now for pain, sleep, or anxiety, can have a more informed conversation with their physician without the assumption that cognitive decline is an inevitable consequence. - 78Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
Emerging longitudinal research is adding to a growing body of evidence suggesting that lifetime cannabis use in older adults does not appear to accelerate cognitive decline or meaningfully elevate dementia risk. This is clinically significant because older adults represent one of the fastest-growing demographics of cannabis users, and concerns about neurological harm have historically discouraged both patient use and physician engagement. The findings invite a more nuanced, evidence-based conversation about risk stratification in aging populations considering cannabis as part of their therapeutic toolkit.
Why it matters: Older adults who use or are considering cannabis for conditions like pain, sleep, or anxiety can discuss this research with their physicians without the added concern that long-term use may increase their risk of cognitive decline or dementia. - 78Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
Researchers in Israel have identified specific cannabinoid compounds that show meaningful activity against non-alcoholic fatty liver disease, a condition affecting hundreds of millions of people worldwide that currently has no approved pharmaceutical treatment. The compounds appear to work through mechanisms involving hepatic fat accumulation, inflammation, and fibrosis pathways, which aligns with what the endocannabinoid system is already known to regulate in metabolic and liver tissue. This represents a significant step toward developing a targeted, cannabinoid-derived therapeutic rather than relying on whole-plant or broad-spectrum products.
Why it matters: For the estimated 100 million Americans living with fatty liver disease and no approved medication options, this research opens a credible pharmaceutical pathway that could eventually produce a first-in-class treatment derived from cannabis compounds. - 78The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
- 78North Shore Dispensary opens in Duluth’s Lincoln Park – WDIO.com
- 78Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
Emerging research suggests that cannabinoids, including both THC and CBD, may play a protective role against the development and progression of non-alcoholic fatty liver disease (NAFLD) by modulating hepatic inflammation, lipid metabolism, and fibrotic pathways through the endocannabinoid system. The liver expresses both CB1 and CB2 receptors, and while CB1 activation has historically been associated with pro-steatotic effects, selective CB2 stimulation appears to confer anti-inflammatory and antifibrotic benefits. This growing body of evidence positions the endocannabinoid system as a legitimate therapeutic target in metabolic liver disease, warranting further rigorous clinical investigation.
Why it matters: For the millions of patients with fatty liver disease who have limited pharmacological options, cannabinoid-based therapies could represent a meaningful new direction in treatment if ongoing clinical trials confirm these early findings. - 76Observational study on medical marijuana use seeks Arizona participants – KJZZ
Observational research on medical cannabis is essential for building the real-world evidence base that controlled trials alone cannot provide, particularly given the diversity of conditions, products, and consumption patterns patients bring to clinical settings. Recruiting participants at the point of initiation allows researchers to capture baseline data and track outcomes longitudinally, which strengthens the quality of findings compared to studies that enroll patients already well into their cannabis use. Arizona’s participation in a national study expands geographic and demographic representation, which helps address longstanding concerns about whether cannabis research reflects the broader patient population. - 76Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
Emerging preclinical research is examining how non-psychoactive cannabinoids, particularly CBD and CBG, may influence hepatic lipid metabolism and reduce fat accumulation in liver tissue. These compounds appear to interact with endocannabinoid receptors and metabolic pathways involved in fatty acid synthesis and inflammation, offering a potential therapeutic avenue for metabolic-associated steatotic liver disease. While results from laboratory and animal models are encouraging, translating these findings into validated clinical protocols for human patients requires rigorous controlled trials to establish effective dosing, safety profiles, and long-term outcomes.
Why it matters: Patients with fatty liver disease or metabolic syndrome may eventually have access to cannabinoid-based therapies as an adjunct treatment option, but only after human clinical trials confirm the safety and efficacy signals seen in early research. - 75A huge study finds a link between cannabis use in teens and psychosis later – KUOW
Large-scale longitudinal research continues to reinforce the clinical concern that adolescent cannabis exposure is associated with elevated risk of psychotic disorders and other serious mental health conditions in adulthood. From a neurobiological standpoint, the adolescent brain is undergoing critical endocannabinoid system maturation, and exogenous cannabinoid exposure during this window may disrupt neurodevelopmental trajectories in ways that increase vulnerability to psychosis, particularly in genetically predisposed individuals. This finding aligns with what we have observed clinically for years and underscores why age-appropriate guidance and delayed initiation remain cornerstones of responsible cannabis medicine.
Why it matters: 🧠 New large-scale research highlights what clinicians have long observed: teen cannabis use is linked to higher psychosis risk later in life. Here’s what you need to know: • 📊 Over 400,000 teens were followed into adulthood • ⚠️ Those who used cannabis showed elevated risk for psychotic disorders • 🧬 The adolescent brain is still maturing, especially the endocannabinoid system • 🛡️ Delaying cannabis use until at least age 25 is a key harm reduction strategy • 💊 Cannabis medicine is powerful, but it is adult medicine As a physician who has treated 30,000+ patients, I believe in cannabis as a therapeutic tool. But responsible use means respecting the science of brain development. Let’s keep the conversation honest. 👇 - 75Prescribed cannabis and driving behaviours among two samples of people who regularly … – UNSW
Research examining driving behaviors among medical cannabis patients raises important questions about how THC affects psychomotor function, reaction time, and judgment at various doses and time points after consumption. The relationship between measured THC levels and actual impairment is complex, as tolerance, route of administration, and individual pharmacokinetics all influence functional capacity behind the wheel. Clinicians prescribing cannabis have a responsibility to counsel patients clearly about timing of use relative to driving, particularly when THC-dominant formulations are involved. - 75Cannabis research: India to start human trials for medicinal marijuana – NewsBytes
India’s launch of human clinical trials for medicinal cannabis represents a significant regulatory and scientific shift for a country with historically strict drug policies. These trials will generate controlled safety and efficacy data across specific medical conditions, helping to establish evidence-based frameworks for potential therapeutic use. Structured human trials are essential for understanding dosing, pharmacokinetics, and therapeutic windows in diverse patient populations, and data from a large and genetically diverse country like India could meaningfully contribute to global cannabis medicine research. - 75Cannabis Munchies Driven by Brain Reward Signals | Technology Networks
Cannabis-induced hyperphagia, colloquially known as “the munchies,” has long been observed clinically but its precise neurological underpinnings in humans have remained incompletely characterized. Emerging research points to cannabis activating reward-related brain circuitry, particularly pathways involving endocannabinoid signaling that amplify the hedonic and motivational aspects of eating. Understanding these mechanisms has meaningful implications not only for recreational use patterns but also for therapeutic applications in conditions involving appetite dysregulation, such as cancer cachexia, HIV-associated wasting, and anorexia nervosa. - 75The association between cannabis use and brain reward anticipation: a 12-month … – Nature
The endocannabinoid system plays a central role in shaping brain reward circuitry, and THC directly engages this system during periods when neural architecture is still actively developing. Research examining cannabis use and reward anticipation over a 12-month period reflects growing scientific interest in how repeated THC exposure may alter dopaminergic signaling and motivational processing. Understanding these neurobiological mechanisms is clinically relevant for evaluating both therapeutic applications and potential risks across different age groups and patterns of use. - 75Screaming, vomiting, and daily weed: The rise of ‘scromiting’ among chronic cannabis users
Cannabinoid hyperemesis syndrome is a paradoxical condition in which heavy, long-term cannabis use causes cyclical episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is thought to involve dysregulation of cannabinoid receptors in the gut and hypothalamus, particularly with chronic high-potency THC exposure, though the precise mechanism remains under active investigation. Definitive resolution typically requires complete cessation of cannabis use, and patients frequently cycle through emergency departments multiple times before receiving an accurate diagnosis.
Why it matters: If you use cannabis daily and experience recurring episodes of severe vomiting that hot showers seem to relieve, you should discuss cannabinoid hyperemesis syndrome with your physician before your next emergency room visit. - 75Study finds no links between cannabis use and cognitive decline or dementia in older people
Concerns about cannabis use accelerating cognitive decline or contributing to dementia risk in older adults have long influenced clinical conversations, but emerging research is beginning to challenge those assumptions. The biological reality is complex, given that the endocannabinoid system plays a regulatory role in neuroinflammation and neuroprotection, and that older adults are using cannabis for legitimate symptom management at increasing rates. Understanding whether cannabis poses a cognitive threat or potentially a neutral or even protective profile in aging populations has significant implications for how clinicians counsel patients over 60.
Why it matters: Older adults who use cannabis for pain, sleep, or anxiety can share this research with their physicians to support more informed, evidence-based conversations about risk rather than assumption-based discouragement. - 75Cannabis Use and Brain Aging: What a Major Study Reveals – Born2Invest
Research drawing on large biobank datasets has examined whether cannabis use is associated with measurable changes in brain aging trajectories. The findings suggest a nuanced picture in which cannabis users may show some initial differences in brain age metrics, but the relationship between cannabis exposure and long-term neurological aging is not straightforwardly harmful or protective. Interpreting these results requires careful attention to confounders such as frequency of use, age of initiation, and whether acute versus chronic effects are being captured.
Why it matters: Patients who use cannabis regularly and are concerned about long-term brain health now have large-scale data to discuss with their physician, though the findings underscore the importance of individualized conversations rather than blanket reassurance or alarm. - 75Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie
Emerging research is challenging long-held assumptions about cannabis use and cognitive aging, with data suggesting that older adults who use cannabis do not show accelerated cognitive decline or increased dementia risk compared to non-users. This is clinically relevant given that older adults are one of the fastest-growing segments of cannabis users, often turning to it for pain, sleep, and anxiety management. Understanding the cognitive safety profile of cannabis in this population helps clinicians counsel patients more accurately and move beyond reflexive caution rooted in outdated assumptions.
Why it matters: Older adults considering cannabis for symptom management can point to this growing body of evidence when discussing cognitive safety concerns with their doctors. - 75Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com
Preclinical and emerging clinical research suggests that certain cannabinoids, particularly CBD and to some extent THC, may help reduce hepatic fat accumulation and inflammation associated with metabolic-associated steatotic liver disease, formerly known as non-alcoholic fatty liver disease. These compounds appear to interact with the endocannabinoid system’s CB1 and CB2 receptors in hepatic tissue, with CB2 activation generally showing protective anti-inflammatory effects while CB1 activation may carry more complex metabolic implications. The findings add to a growing body of evidence suggesting cannabinoids could play a role in managing metabolic liver conditions, though rigorous human clinical trials remain limited.
Why it matters: Patients managing metabolic syndrome, obesity, or early-stage fatty liver disease may want to discuss cannabinoid-based options with their physician as this area of research continues to develop. - 74Placental Changes From Prenatal Cannabis Exposure Could Flag Higher Schizophrenia …
Emerging research suggests that prenatal cannabis exposure may produce measurable epigenetic and gene expression changes in placental tissue, particularly in pathways associated with neurodevelopmental risk including schizophrenia. The placenta, long underappreciated as a window into fetal programming, appears to reflect cannabis-related disruptions that could correlate with altered brain development trajectories in offspring. This line of investigation raises important questions about the biological mechanisms linking gestational cannabis use to psychiatric vulnerability later in life.